Last reviewed · How we verify
elvitegravir/cobicistat/emtricitabine/tenofovir
elvitegravir/cobicistat/emtricitabine/tenofovir is a Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs) Small molecule drug developed by Juan A. Arnaiz. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing). Also known as: Stribild.
This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase.
This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
At a glance
| Generic name | elvitegravir/cobicistat/emtricitabine/tenofovir |
|---|---|
| Also known as | Stribild |
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs) |
| Target | HIV integrase, CYP3A4, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Elvitegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Cobicistat is a pharmacokinetic booster that inhibits CYP3A4, increasing elvitegravir levels. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that block reverse transcriptase and prevent viral RNA conversion to DNA. Together, these agents target multiple steps of the HIV replication cycle.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Elevated creatinine
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Early ART to Limit Infection and Establishment of Reservoir (PHASE2)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- elvitegravir/cobicistat/emtricitabine/tenofovir CI brief — competitive landscape report
- elvitegravir/cobicistat/emtricitabine/tenofovir updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI
Frequently asked questions about elvitegravir/cobicistat/emtricitabine/tenofovir
What is elvitegravir/cobicistat/emtricitabine/tenofovir?
How does elvitegravir/cobicistat/emtricitabine/tenofovir work?
What is elvitegravir/cobicistat/emtricitabine/tenofovir used for?
Who makes elvitegravir/cobicistat/emtricitabine/tenofovir?
Is elvitegravir/cobicistat/emtricitabine/tenofovir also known as anything else?
What drug class is elvitegravir/cobicistat/emtricitabine/tenofovir in?
What development phase is elvitegravir/cobicistat/emtricitabine/tenofovir in?
What are the side effects of elvitegravir/cobicistat/emtricitabine/tenofovir?
What does elvitegravir/cobicistat/emtricitabine/tenofovir target?
Related
- Drug class: All Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs) drugs
- Target: All drugs targeting HIV integrase, CYP3A4, HIV reverse transcriptase
- Manufacturer: Juan A. Arnaiz — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in adolescents and children (weight-based dosing)
- Also known as: Stribild
- Compare: elvitegravir/cobicistat/emtricitabine/tenofovir vs similar drugs
- Pricing: elvitegravir/cobicistat/emtricitabine/tenofovir cost, discount & access